Current diagnosis of acromegaly

Area of Science:

• Endocrinology
• Oncology
• Biochemistry

Background:

• Acromegaly results from sustained hypersecretion of growth hormone (GH), typically caused by pituitary adenomas.
• Excess GH and insulin-like growth factor-1 (IGF-1) lead to significant morbidity and increased mortality.
• Early diagnosis is critical for improving survival and quality of life.

Purpose of the Study:

• To review the diagnostic evolution of acromegaly.
• To highlight the importance of biochemical testing in acromegaly diagnosis.
• To discuss ongoing debates in interpreting diagnostic criteria.

Main Methods:

• Historical review of diagnostic methodologies for acromegaly.
• Discussion of radioimmunoassay (RIA) and newer immunometric assays (IRMA, ILMA) for GH and IGF-1.
• Analysis of current consensus on diagnostic approaches.

Main Results:

• Radioimmunoassay (RIA) was an early diagnostic tool, but newer, more sensitive assays like IRMA and ILMA are now used.
• Despite assay improvements, reference ranges and biochemical cure criteria for acromegaly are subjects of debate.
• Diagnosis relies on integrating clinical presentation with biochemical data.

Conclusions:

• Accurate diagnosis of acromegaly is essential for patient management and prognosis.
• Biochemical assays have evolved, enhancing diagnostic capabilities for acromegaly.
• A consensus exists that acromegaly diagnosis requires a combination of clinical and biochemical evidence.